Dariohealth corp.DRIO.US Overview
DRIO Overall Performance
DRIO AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
DRIO Current Performance
-6.58%
Dariohealth corp.
-0.47%
Avg of Sector
-0.64%
S&P500
DRIO Key Information
DRIO Financial Forecast
Browsing restrictions can be lifted for a fee.
| Quarterly | EPS Forecast | QoQ | Max | Min |
|---|---|---|---|---|
| 2025Q1 | ||||
| 2025Q2 | ||||
| 2025Q3 | ||||
| 2025Q4 | ||||
| 2026Q1 |
DRIO Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
DRIO Profile
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Price of DRIO
DRIO FAQ
When is DRIO's latest earnings report released?
The most recent financial report for Dariohealth corp. (DRIO) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DRIO's short-term business performance and financial health. For the latest updates on DRIO's earnings releases, visit this page regularly.
What is the operating profit of DRIO?
According to the latest financial report, Dariohealth corp. (DRIO) reported an Operating Profit of -9.2M with an Operating Margin of -171.35% this period, representing a growth of 43.18% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.
How is DRIO's revenue growth?
In the latest financial report, Dariohealth corp. (DRIO) announced revenue of 5.37M, with a Year-Over-Year growth rate of -14.16%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.
How much debt does DRIO have?
As of the end of the reporting period, Dariohealth corp. (DRIO) had total debt of 31.62M, with a debt ratio of 0.29. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does DRIO have?
At the end of the period, Dariohealth corp. (DRIO) held Total Cash and Cash Equivalents of 21.95M, accounting for 0.2 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Does DRIO go with three margins increasing?
In the latest report, Dariohealth corp. (DRIO) did not achieve the “three margins increasing” benchmark, with a gross margin of 55.2%%, operating margin of -171.35%%, and net margin of -345.7%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess DRIO's profit trajectory and future growth potential.
Is DRIO's EPS continuing to grow?
According to the past four quarterly reports, Dariohealth corp. (DRIO)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -3.6. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of DRIO?
Dariohealth corp. (DRIO)'s Free Cash Flow (FCF) for the period is -6.08M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 46.67% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of DRIO?
The latest valuation data shows Dariohealth corp. (DRIO) has a Price-To-Earnings (PE) ratio of -0.33 and a Price/Earnings-To-Growth (PEG) ratio of 0. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.